Cabozantinib shows clinically meaningful improvement in advanced neuroendocrine tumours

Share :
Published: 7 Nov 2023
Views: 25
Dr Jennifer Chan - Dana-Farber Cancer Institute, Boston, USA

Dr Jennifer Chan speaks to ecancer at ESMO 2023 about the Alliance A021602 study.

This was a phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumours after progression on prior therapy.

The results show cabozantinib as having a statistically significant and clinically meaningful improvement in progression free survival in extra-pancreatic neuroendocrine tumours and pancreatic neuroendocrine tumours. Cabozantinib may be a new treatment option for patients with previously treated, progressive neuroendocrine tumours.